account_balance
Investment manager · 13F filer · SEC CIK 1633313
Avoro Capital Advisors LLC
Reported value$11.1Bas of Jun 30, 2026
Positions26 3 new, 7 sold out
Top 10 weight79.5%UTHR alone is 14%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
UTHRUnited Therapeutics Corp
13.5%Added +6%
ASNDAscendis Pharma
12.2%New
KRYSKrystal Biotech Inc
9.6%
MDGLMadrigal Pharmaceuticals Inc
8.8%
ARGXArgenx Se
8.3%
ARWRArrowhead Pharmaceuticals Inc
8.3%Added +6%
KYMRKymera Therapeutics Inc
7.7%
RVMDRevolution Medicines Inc
3.9%Trimmed −2%
CYTKCytokinetics Inc
3.8%Added +50%
CELCCelcuity Inc
3.2%
GPCRStructure Therapeutics Inc
3.2%
XENEXenon Pharmaceuticals Inc
3.1%
UTHRUnited Therapeutics Corp
13.5%Added +6%
ASNDAscendis Pharma
12.2%New
KRYSKrystal Biotech Inc
9.6%
MDGLMadrigal Pharmaceuticals Inc
8.8%
ARGXArgenx Se
8.3%
ARWR8.3%KYMR7.7%RVMD3.9%CYTK3.8%CELC3.2%GPCR3.2%XENE3.1%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
UTHR United Therapeutics Corp 13.5% Added +6%ASND Ascendis Pharma 12.2% NewKRYS Krystal Biotech Inc 9.6% HeldMDGL Madrigal Pharmaceuticals Inc 8.8% HeldARGX Argenx Se 8.3% HeldARWR Arrowhead Pharmaceuticals Inc 8.3% Added +6%KYMR Kymera Therapeutics Inc 7.7% HeldRVMD Revolution Medicines Inc 3.9% Trimmed −2%CYTK Cytokinetics Inc 3.8% Added +50%CELC Celcuity Inc 3.2% HeldGPCR Structure Therapeutics Inc 3.2% HeldXENE Xenon Pharmaceuticals Inc 3.1% Held
What changed